+

PE20070645A1 - Compuestos heterociclicos como moduladores de la beta-secretasa - Google Patents

Compuestos heterociclicos como moduladores de la beta-secretasa

Info

Publication number
PE20070645A1
PE20070645A1 PE2006001476A PE2006001476A PE20070645A1 PE 20070645 A1 PE20070645 A1 PE 20070645A1 PE 2006001476 A PE2006001476 A PE 2006001476A PE 2006001476 A PE2006001476 A PE 2006001476A PE 20070645 A1 PE20070645 A1 PE 20070645A1
Authority
PE
Peru
Prior art keywords
beta
acetamide
tetrahydro
alkenyl
amino
Prior art date
Application number
PE2006001476A
Other languages
English (en)
Inventor
Wenge Zhong
Stephen Hitchcock
Brian K Albrecht
Michael Bartberger
James Brown
Ryan Brown
Stuart Charles Chaffee
Yuan Cheng
Michael Croghan
Russell Graceffa
Scott Harried
Dean Hickman
Daniel Horne
Randall W Hungate
Ted Judd
Matthew Kaller
Charles Kreiman
Daniel La
Patricia Lopez
Craig E Masse
Holger Monenschein
Thomas Nguyen
Thomas Nixey
Vinod F Patel
Lewis Pennigton
Matthew Weiss
Qiufen Xue
Bryant Yang
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39708735&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20070645(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of PE20070645A1 publication Critical patent/PE20070645A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C07D311/68—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with nitrogen atoms directly attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Quinoline Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Furan Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

SE REFIERE A COMPUESTOS DE FORMULA (I) DONDE A ES ALQUILO(C1-C10), ALQUENILO(C2-C10), ALQUINILO(C2-C10), ENTRE OTROS; W ES -C(=O)-, -OC(=O)-, -NHC(=O)-, ENTRE OTROS; B ES R2-(CR2aR2a)h-, R2-O-(CR2aR2a)h, ENTRE OTROS, DONDE R2 ES ALQUILO(C1-C10), HALOALQUILO(C1-C10), ALQUENILO(C2-C10), ENTRE OTROS; R2a ES H, OH, NO2, CN, ENTRE OTROS; h ES DE 0 A 3; i ES DE 1 A 3; j ES DE 0 A 2; R3 ES H, CN, ALQUILO(C1-C10), ENTRE OTROS; R4 ES H, CN, ALQUENILO(C2-C10), ENTRE OTROS; R5 ES UN COMPUESTO DE FORMULA (a), (b), (c), ENTRE OTROS; DONDE X1 ES CR12, O, S O NR12; X2 ES CR12R12; Y1, Y2 E Y3 SON CADA UNO CR12R12, O, S O NR12; m ES DE 0 A 2; o ES DE 0 A 5; R10 ES H, HALO, CN, OH, ENTRE OTROS; R12 ES H, HALO, NH2, NO2, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: N-((1S,2R)-2-HIDROXI-1-(FENILMETIL)-3-(((4S)-2,6,6-TRIMETIL-4,5,6,7-TETRAHIDRO-1-BENZOFURAN-4-IL)AMINO)PROPIL)ACETAMIDA, N-((1S,2R)-3-(((4S)-2-ETIL-6,6-DIMETIL-4,5,6,7-TETRAHIDRO-1-BENZOTIEN-4-IL)AMINO)-2-HIDROXI-1-(FENILMETIL)PROPIL)-2-(2-OXO-1-PIRROLIDINIL)ACETAMIDA, N-((1S,2R)-1-((3-CIANOFENIL)METIL)-3-(((1R)-3,3-DIMETIL-7-(METILOXI)-4-OXO-1,2,3,4-TETRAHIDRO-1-NAFTALENIL)AMINO)-2-HIDROXIPROPIL)-2-(METILOXI)ACETAMIDA, ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA Y A UN PROCEDIMIENTO DE PREPARACION. DICHOS COMPUESTOS SON MODULADORES DE LA ENZIMA BETA-SECRETASA SIENDO UTILES EN EL TRATAMIENTO DE LA ENFERMEDAD DE ALZHEIMER
PE2006001476A 2005-11-21 2006-11-20 Compuestos heterociclicos como moduladores de la beta-secretasa PE20070645A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73910805P 2005-11-21 2005-11-21
US85482406P 2006-10-27 2006-10-27

Publications (1)

Publication Number Publication Date
PE20070645A1 true PE20070645A1 (es) 2007-08-24

Family

ID=39708735

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2006001476A PE20070645A1 (es) 2005-11-21 2006-11-20 Compuestos heterociclicos como moduladores de la beta-secretasa

Country Status (8)

Country Link
EP (1) EP1971598A1 (es)
JP (1) JP5274258B2 (es)
AR (1) AR057985A1 (es)
AU (1) AU2006316620B2 (es)
CA (1) CA2629402C (es)
PE (1) PE20070645A1 (es)
TW (1) TW200800966A (es)
WO (1) WO2007061670A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7763609B2 (en) 2003-12-15 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
WO2008147544A1 (en) * 2007-05-25 2008-12-04 Amgen Inc. Substituted hydroxyethyl amine compounds as beta-secretase modulators and methods of use
CL2008001500A1 (es) * 2007-05-25 2008-12-26 Amgen Inc Compuestos derivados de hidroxietil amina sustituidas, moduladores de betasecretasa; proceso de preparacion de dichos c ompuestos; composicion farmaceutica que los comprende; y su uso para tratar un trastorno neurologico, tal como alzheimer, sindrome de down, demencia degenerativa, entre otros.
CN103687839B (zh) 2011-07-21 2016-06-08 通用电气健康护理有限公司 前体化合物及其制备方法
AU2013235117A1 (en) * 2012-03-20 2014-10-16 Dean R. Artis Spirocyclic dihydro-thiazine and dihydro-oxazine bace inhibitors, and compositions and uses thereof
JP6562361B2 (ja) * 2014-07-16 2019-08-21 国立研究開発法人科学技術振興機構 ベンゾチアゾール化合物及びこれを含有する医薬
US12240855B2 (en) 2019-03-06 2025-03-04 Daiichi Sankyo Company, Limited Pyrrolopyrazole derivative

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY138097A (en) 2000-03-22 2009-04-30 Du Pont Insecticidal anthranilamides
NZ523005A (en) 2000-06-30 2004-11-26 Elan Pharm Inc Compounds to treat alzheimer's disease
US7196163B2 (en) 2001-05-22 2007-03-27 Merk & Co., Inc. Assays using amyloid precursor proteins with modified β-secretase cleavage sites to monitor β-secretase activity
EP1401452A1 (en) 2001-06-27 2004-03-31 Elan Pharmaceuticals, Inc. Beta-hydroxyamine derivatives useful in the treatment of alzheimer's disease
KR100713137B1 (ko) 2001-06-28 2007-05-02 동화약품공업주식회사 신규의 2,4-디플루오로벤즈아미드 유도체
BR0211122A (pt) 2001-07-10 2004-10-26 Elan Pharm Inc Composto, métodos para o tratamento ou prevenção de doenças e para fabricar um composto, intermediário, e, uso de um composto ou sal
US7067542B2 (en) 2001-07-10 2006-06-27 Pharmacia & Upjohn Company Diaminediols for the treatment of Alzheimer's disease
DE60234696D1 (de) 2001-07-11 2010-01-21 Elan Pharm Inc N-(3-amino-2-hydroxy-propyl)substituierte alkylamidverbindungen
US7244755B2 (en) 2001-10-04 2007-07-17 Pharmacia & Upjohn Company Hydroxypropylamines
US20050027007A1 (en) 2001-10-05 2005-02-03 Roy Hom Allylamides useful in the treatment of alzheimer's disease
US20050038019A1 (en) 2001-10-29 2005-02-17 Beck James P. Hydroxy substituted amides for the treatment of alzheimer's disease
BR0214035A (pt) 2001-11-08 2005-04-26 Elan Pharm Inc Composto
TW200304374A (en) 2001-11-30 2003-10-01 Smithkline Beecham Plc Novel compounds
US7312360B2 (en) 2001-12-06 2007-12-25 Elan Pharmaceuticals, Inc. Substituted hydroxyethylamines
CA2472617A1 (en) 2002-01-04 2003-07-17 Elan Pharmaceuticals, Inc. Substituted amino carboxamides for the treatment of alzheimer's disease
TW200406390A (en) 2002-01-17 2004-05-01 Neurogen Corp Substituted quinazolin-4-ylamine analogues
US7132568B2 (en) 2002-06-17 2006-11-07 Sunesis Pharmaceuticals, Inc. Aspartyl protease inhibitors
PL374999A1 (en) 2002-06-20 2005-11-14 Pharmacia & Upjohn Company Llc Process for preparing 5-(1, 3-oxazol-2-yl) benzoic acid derivatives
UY27967A1 (es) * 2002-09-10 2004-05-31 Pfizer Acetil 2-hindroxi-1,3-diaminoalcanos
US7362070B2 (en) 2002-11-04 2008-04-22 Hamilton Sundstrand Corporation Electric motor control system including position determination and error correction
AU2003291308B2 (en) 2002-11-12 2009-06-18 Merck & Co., Inc. Phenylcarboxamide beta-secretase inhibitors for the treatment of Alzheimer's disease
DOP2003000765A (es) * 2002-11-27 2004-05-31 Elan Fharmaceuticals Inc Ureas substituidas y carbamatos utiles para el tratamiento de la enfermedad de alzheimer (substituted ureas and carbamates useful in the treatment of alzheimer`s disease
GB0228410D0 (en) 2002-12-05 2003-01-08 Glaxo Group Ltd Novel Compounds
CA2512111A1 (en) 2003-01-07 2004-07-29 Merck And Co., Inc. Macrocyclic beta-secretase inhibitors for treatment of alzheimer's disease
GB0305918D0 (en) 2003-03-14 2003-04-23 Glaxo Group Ltd Novel compounds
JP2006520371A (ja) 2003-03-14 2006-09-07 メルク　シャープ　エンド　ドーム　リミテッド 軽症の認識損傷の治療方法及びアルツハイマー病の予防又は遅延方法
AR044043A1 (es) 2003-04-21 2005-08-24 Elan Pharm Inc Fenacilo 2-hidroxi-3-diaminoalcanos
MXPA05011150A (es) 2003-04-21 2005-12-14 Elan Pharm Inc 2-hidroxi-3-diaminoalcanos de benzamida.
GB0309221D0 (en) * 2003-04-23 2003-06-04 Glaxo Group Ltd Novel compounds
AU2003297826A1 (en) 2003-06-16 2005-01-28 Sunesis Pharmaceuticals, Inc Aspartyl protease inhibitors
JP2007516207A (ja) 2003-06-30 2007-06-21 メルク　エンド　カムパニー　インコーポレーテッド アルツハイマー病の治療のためのＮ−アルキルフェニルカルボキサミドβ−セクレターゼ阻害剤
CN1909897A (zh) 2003-07-01 2007-02-07 默克公司 用于治疗阿尔茨海默病的苯基羧化物β－分泌酶抑制剂
GB0317491D0 (en) * 2003-07-25 2003-08-27 Novartis Ag Organic compounds
WO2005070407A1 (en) * 2004-01-21 2005-08-04 Elan Pharmaceuticals, Inc. Methods of treatment of amyloidosis using aspartyl-protease inihibitors
WO2005087714A2 (en) * 2004-03-09 2005-09-22 Elan Pharmaceuticals, Inc. Methods of treatment of amyloidosis using bi-cyclic aspartyl protease inhibitors
EP1751091A2 (en) * 2004-03-25 2007-02-14 Elan Pharmaceuticals, Inc. 2-amino- and 2-thio-substituted 1,3-diaminopropanes

Also Published As

Publication number Publication date
AU2006316620A1 (en) 2007-05-31
AR057985A1 (es) 2008-01-09
CA2629402C (en) 2011-07-26
WO2007061670A1 (en) 2007-05-31
JP2009516684A (ja) 2009-04-23
CA2629402A1 (en) 2007-05-31
TW200800966A (en) 2008-01-01
EP1971598A1 (en) 2008-09-24
JP5274258B2 (ja) 2013-08-28
AU2006316620B2 (en) 2011-03-03

Similar Documents

Publication Publication Date Title
PE20070645A1 (es) Compuestos heterociclicos como moduladores de la beta-secretasa
RU2418792C2 (ru) Азольные соединения с нейтротерапевтической активностью
EE200300403A (et) N-asendatud mittearomaatne heterotsükliline ühend, seda sisaldav ravimkompositsioon ning ühendi kasutamine ravimina
NO20062677L (no) Benzyleteraminforbindelser anvendbare som CCR-5-antagonister
EA200700117A1 (ru) N-замещенные пиперидины и их применение в качестве фармацевтических препаратов
PE20061124A1 (es) Compuestos y derivados de dibencil amina
ATE360631T1 (de) Azabicyclische heterocyclen als modulatoren des cannabinoidrezeptors
ATE370141T1 (de) Antidiabetische heterocyclische beta- aminoverbindungen als inhibitoren von dipeptidylpeptidase
DE60316416D1 (de) Heterocyclische beta-aminoverbindungen als inhibitoren der dipeptidylpeptidase zur behandlung bzw. prävention von diabetes
UY27368A1 (es) Nuevos compuestos
PE20050420A1 (es) Fenacilo 2-hidroxi-3-diaminoalcanos
PE20070218A1 (es) COMPUESTOS DE CICLOALQUILO AMINO-HIDANTOINA Y USO DE ESTOS PARA LA MODULACION DE ß-SECRETASA
BRPI0409227B8 (pt) "composto, composição farmacêutica, uso de um composto e processo para a preparação de um composto de fórmula (i)"
BR0012804A (pt) Derivados de amina e amida como ligandos para o receptor de neuropeptìdeo y y5 útil no tratamento da obesidade e outros distúrbios
PE20110367A1 (es) DERIVADOS DE 4-CIANO-4-FENIL-PIRROLIDIN-2-CARBOXAMIDAS SUSTITUIDAS COMO INHIBIDORES DE LA INTERACCION p53-MDM2
TNSN06109A1 (fr) Derives [3.1.0] bicycliques servant d'inhibiteurs du transporteur de glycine
EA200700489A1 (ru) Новые бензоконденсированные гетероарилсульфамидные производные, полезные в качестве противоконвульсивных средств
BRPI0514738A (pt) derivados de amida de 3-fenil-diidropirimido[4,5-d]pirimidinonas, sua fabricação e aplicação como agentes farmacêuticos
DK1885333T3 (da) Farmaceutisk formulering af apomorphin til bukkal indgivelse
BR0310077A (pt) Novos compostos e sua utilização
DK1776349T3 (da) 2-amino-puinazolin derivater anvendelige som inhibitorer af beta-sekretase (BACE)
MA31889B1 (fr) N-phenyl -bipyrrolidine-urees substituees et utilisation therapeutique de celles-ci
ATE517861T1 (de) Benzylether und benzylaminoverbindungen als inhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
HRP20050262A2 (en) Pyrrolidone derivatives as maob inhibitors
MXPA04008152A (es) Compuestos azabiciclicos para el tratamiento de enfermedades.

Legal Events

Date Code Title Description
FD Application declared void or lapsed
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载